This website is intended for healthcare professionals only.
CONTINUUM OF CARE IN mPaCa: WHICH STRATEGY FOR OUR PATIENTS?
Professor Gerald Prager Associate Professor of Oncology Head of Gastrointestinal Cancer Program Medical University of Vienna, Austria
This webinar presents the challenges faced when treating metastatic pancreatic cancer (mPaCa) and the potential strategies to improve patients outcomes. The clinical trial results and real-world evidence for 1L, 2L and 3L treatment options are discussed, as well as the potential of molecular profiling for additional treatment options.
Key points covered
This webinar highlights the current treatment strategies for mPaCa.
1L treatment options have improved prognosis, providing a continuum of care in more and more patients
New 2L options have recently been introduced, including Nal-IRI + 5-FU/LV post-gemcitabine
Molecular profiling may offer additional treatment options to a subgroup of patients
Webinar Replay
Featured Speaker
Professor Gerald Prager
Prof Prager is the Director of the GI Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center, Vienna. He leads the Unit for Precision Medicine in Cancer and is an Associate Professor of Medicine, Board Certified for Internal Medicine, Hematology, and Medical Oncology. Prof Prager graduated from the Medical School of the University of Vienna and completed his postdoctoral training at the University of California, San Diego, USA and was a Visiting Professor at the Norris Cancer Center, University of Southern California, Los Angeles, USA in 2011. Prof Prager’s main research interests focus on translational research and (tumor-) angiogenesis and his works have been honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
